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Hypertension and diabetes treatment
affordability and government expenditures
following changes in patient cost sharing in
the “Farmácia popular” program in Brazil:
an interrupted time series study
Isabel Cristina Martins Emmerick1,2* , Mônica Rodrigues Campos3, Rondineli Mendes da Silva4,
Luisa Arueira Chaves5, Andréa Dâmaso Bertoldi6, Dennis Ross-Degnan7 and Vera Lucia Luiza4
Abstract
Background: Increasing medicines availability and affordability is a key goal of Brazilian health policies. “Farmácia
Popular” (FP) Program is one of the government’s key strategies to achieve this goal. Under FP, antihypertension
(HTN) and antiglycemic (DM) medicines have been provided at subsidized prices in private retail settings since
2006, and free of charge since 2011. We aim to assess the impact of sequential changes in FP benefits on patient
affordability and government expenditures for HTN and DM treatment under the FP, and examine their implications
for public financing mechanisms and program sustainability.
Methods: Longitudinal, retrospective study using interrupted time series to analyze: HTN and DM treatment coverage;
total and per capita expenditure; percentage paid by MoH; and patient cost sharing. Analyzes were conducted in the
dispensing database of the FP program (from 2006 to 2012).
Results: FP has increased its coverage over time; by December 2012 FP covered on average 13% of DM and 11.5% of
HTN utilization, a growth of over 600 and 1500%, respectively. The overall cost per treatment to the MoH declined
from R$36.43 (R$ = reais, the Brazilian currency) to 18.74 for HTN and from R$33.07to R$15.05 for DM over the period
analyzed, representing a reduction in per capita cost greater than 50%. The amount paid by patients for the medicines
covered increased over time until 2011, but then declined to zero. We estimate that to treat all patients in need for
HTN and DM in 2012 under FP, the Government would need to expend 97% of the total medicines budget.
Conclusions: FP rapidly increased its coverage in terms of both program reach and proportion of cost subsidized
during the period analyzed. Costs of individual HTN and DM treatments in FP were reduced after 2011 for both
patients (free) and government (better negotiated prices). However, overall FP expenditures by MoH increased due to
markedly increased utilization. The FP is sustainable as a complementary policy but cannot feasibly substitute for the
distribution of medicines by the SUS.
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Background
Treatment of hypertension (HTN) and diabetes (DM) is
considered a health policy priority in Brazil, with par-
ticular attention paid to reducing preventable hospital
admissions. Recent reductions have been associated with
the expansion of the primary care, which facilitates early
detection, and treatment of HTN and DM [1].
The main characteristics of the principal medicines
provision mechanisms in place in Brazil are summarized
in Table 4 in Appendix. Access to medicines and health
care is universal [2] and there is no barrier to obtaining
medicines from different sources. Patients can obtain
medicines free at public health facilities, through “Farm-
ácia Popular” (FP), or by paying out-of-pocket at private
retail pharmacies simultaneously.
The “Farmácia Popular” (FP) is a medicines provision
mechanism first implemented in 2004. In its first phase,
medicines were provided in public health care facilities at
a flat price, corresponding to the price obtained by the
government in open bidding, plus administrative costs.
This program was named “Farmacia Popular Rede Pró-
pria”. In 2006 the program, then named “Aqui tem Farm-
acia Popular - AFP” (“Farmácia Popular” is available
here- AFP-I), was expanded to private pharmacies
contracted with the Ministry of Health. Medicines were
charged in a coinsurance model, with the government
paying 90% of a reference price and patients paying 10%
of the selling price (which might be higher than the refer-
ence price). To improve accountability of pharmacies, a
new administrative system was implemented in 2009
(AFP-II) that provided information on each patient claim.
Subsequently, antihypertensive, antidiabetic (since
2011), and antiasthma medicines (since 2012) began to
be dispensed with zero copayment from patients in both
government-owned facilities (n = 558) [3] and contracted
private pharmacies (n = 25,150, covering 63.4% of the
5570 municipalities [3]). This change was named as
“Saúde não tem preço - SNP” (Health has no price). Ex-
cept for metformin 500 mg (extended release), all medi-
cines covered in FP for these three conditions that are
included in RENAME (the National Essential Medicines
List) were provided free-of-charge in SUS. The SNP
makes treatment affordable for patients, but this benefit
might be unsustainable in the long term, especially in a
country that has other forms of provision.
Currently, the FP program continues to provide free
medications for treatment of asthma, diabetes and
hypertension, and co-finances drugs for treatment of
dyslipidemia, osteoporosis, rhinitis, Parkinson’s and glau-
coma, as well as contraceptives and geriatric diapers, to-
taling approximately R$2.9 billion in 2017 [4].
FP is widely seen as a successful program that has ex-
panded coverage in both the number of individuals
treated for DM and HTN and in the number of
dispensings per person [5–7]. However, a number of
studies have cautioned about the program’s high expen-
ditures [8, 9]. On the other hand, the FP program has
been associated with reduced rates of hospital admis-
sions and mortality per 100,000 inhabitants [4]. In paral-
lel with increased government expenditures, families’
health expenditures have also been increasing [10], espe-
cially for medicines. It is thus relevant to examine the
impact of FP on both government expenditures and
medicines affordability.
This paper aims to analyze the impact of the sequen-
tial Farmácia Popular interventions on patient afford-
ability and government expenditures for HTN and DM
treatment under the FP program, and consider their im-
plications for public financing mechanisms and program
sustainability.
Methods
This is a longitudinal, retrospective study using inter-
rupted time series (ITS) to examine out-of-pocket pay-
ments and MoH expenditures for HTN and DM
treatment. The main outcomes addressed are rates of
HTN and DM treatment coverage, number of individ-
uals in FP, total expenditures, percentages paid by MoH,
treatment cost per capita and out of pocket payment.
The Brazilian National Ethics Committee, by the Na-
tional School of Public Health – Fiocruz – Brazil and
the WHO ERC, approved the ISAUM-Br project, which
is the basis for this paper.
Interventions
The study interventions are two changes in patient cost
sharing in AFP. The April 2009 AFP-II policy involved a
reduction in reference prices for most FP medicines by
an average of 24.5%, coupled with administrative
changes aiming to improve accountability. In February
2011, the “Saúde não tem preço” (SNP) program was im-
plemented, under which all covered medicines for HTN
and DM were dispensed free of charge to patients. FP
private pharmacies were reimbursed according to a set
of negotiated prices, while in government-owned phar-
macies, medicines were fully subsidized. Only FP private
pharmacies are addressed in this paper.
Data source and study population
The FP information system is the first widespread gov-
ernmental administrative system on medicines dispens-
ing in Brazil. The FP information system in contracted
pharmacies is managed by the Unified Health System In-
formatics Department (DATASUS). Data include patient
unique identification number (CPF), price paid, date of
purchase, prescribed daily dose and amount procured.
CPF allows linking to data on gender and date of birth.
In the majority of cases, the buyer corresponds to the
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patient for patients over 18 years old. Other adminis-
trative systems cover a small set of medicines (e.g.
ARVs, high cost medicines) and are not integrated at
national level.
FP program eligibility criteria have remained un-
changed during the program: all medicines are sold only
if a national ID and a valid prescription are presented.
During the study period medicines were dispensed on a
monthly basis, although prescriptions were valid for 120
days. Over time, the number of participating private sec-
tor pharmacies expanded substantially, especially in
some regions [3].
Data are derived from an electronic point-of-sales dis-
pensing program implemented in 2006 in FP retail phar-
macies and then integrated online by DATASUS.
Available data include patient and pharmacy identifiers,
patient age and gender, geographic location of the phar-
macy, date of dispensing, name and quantity of medicine
dispensed, daily prescribed dose, amount of MoH reim-
bursement, and patient copayment.
We use data on dispensing of HTN and DM medi-
cines from October 2006 to December 2012. All patients
with at least one dispensing during the study period
were included in this analysis. Dispensing data are of
good quality and relatively complete, with duplicate
cases accounting for less than 0.005% and individual-
level missing data at less than 0.05%. We excluded en-
counters with missing data on any outcome variables
from all analyses.
Medicines covered by the program include four oral
antidiabetic medications (glibenclamide 5mg, and metfor-
min 500mg, 850mg, and slow release 500mg formula-
tions), insulin NPH and regular and six antihypertensive
medications (atenolol 25mg, propranolol 40mg, hydro-
chlorothiazide 25mg, captopril 25mg, enalapril 5 mg, and
losartan 50mg).
Analysis
We analyzed five study outcomes related to FP program
coverage, MoH expenditures, and affordability, as
follows:
1) Monthly number of individuals who received at
least one dispensing at AFP pharmacies;
2) Total monthly program expenditure in reais (Brazil-
ian currency), including total MoH expenditure and total
patient payments;
3) Monthly percentage of expenditure paid by the
MoH;
4) Monthly expenditure per treatment (per capita),
which is the total monthly expenditure divided by the
number of individuals in the program; and.
5) Average monthly out-of-pocket payment, which is
the average amount paid by patients per treatment.
Annual inflation was a relatively stable 3 to 7% during
the study period. We performed a monthly inflation cor-
rection for all financial outcomes [11]. We report all fi-
nancial outcomes in 2012 inflation-adjusted Brazilian
reais; the exchange ratio during the study period was
roughly 2 Brazilian reais to 1 US dollar [12].
As an indicator of potential program sustainability, we
estimated the level of expenditure that would be needed
to fully cover all individuals in Brazil with DM and HTN
through the FP program, and calculated the percentage
that would represent of total MoH expenditures on
medicines, yearly from 2006 to 2012.
It has been demonstrated that most people with HTN
and DM diagnoses, respectively 95 and 85%, are under
pharmacological treatment in Brazil [13]. Thus, it seems
fair to use national prevalence to estimate potential FP
costs, assuming that all patients were treated through
the program. The costs per individual treated in the pro-
gram consider the average cost per capita per type of
disease HTN or DM.
To create this sustainability measure, we first devel-
oped two measures estimating annual FP program
utilization: a) Number of unique individuals with at least
one dispensing within a given year; b) Average number
of individuals receiving at least one dispensing per
month, averaged across 12 months in a given year (i.e.,
allowing individuals to repeat across months). We used
these to construct annual and monthly estimates of pro-
gram coverage, where the denominator of each measure
is an estimate of the annual prevalence of each disease
in Brazil, as a proxy for the number of individuals who
should be under treatment [14].
In addition to deriving yearly coverage estimates using
FP program data, we also used the FP coverage estimates
reported in the following surveys: National Program for
Improving Access and Quality of Primary Health Care
(Programa Nacional de Melhoria do Acesso e da Quali-
dade da Atenção Básica - PMAQ-AB) [15], Brazilian Sur-
vey on Medicine Access, Utilization and Rational Use of
Medicines (Pesquisa Nacional sobre acesso e utilização e
promoção do Uso Racional de Medicamentos – PNAUM)
[13], Surveillance of risk-factor for chronic diseases
through telephone interviews (Vigilância de fatores de
risco e proteção para doenças crônicas por inquérito telefô-
nico – VIGITEL [14] and National Health Survey (Pes-
quisa Nacional de Saúde – PNS) [16].
We did not adjust the monetary values used in this
analysis for inflation, since we are comparing the pro-
portions of expenditures in each year, and not actual ex-
penditures themselves.
Statistical methods
To analyze the impact of Farmácia Popular interven-
tions on affordability and MoH expenditures, we used
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ITS segmented linear regression models to determine
the effect of the FP policy changes on the study out-
comes. In estimating effects, ITS models adjust for pre-
existing trends in the period before the policy change
[17]. Segmented linear regression models were con-
structed using the “prais , corc” command in STATA
v12 [18], we analyzed linearity and autocorrelation. ITS
considered to be one of the strongest quasi-experimental
design to evaluate longitudinal effects of interventions,
while segmented regression analysis is a commonly used
statistical method for estimating intervention effects in
ITS studies [17–22].
Our ITS models included three segments, baseline and
one for each of the two program periods, with 29, 22, and
23 monthly observations, respectively. The segmented re-
gression model was specified as follow [17, 20]:
Y t ¼ β0 þ β1montht þ β2AFPIIt
þ β3months after AFPIIt þ β4AFPt
þ β5months after SNPt þ et
In this model, time (t) is a continuous variable indicat-
ing time in months from the start of the observation
period; Yt = outcome variable in month t; β0 = level at
the start of the observation period (intercept); β1 = base-
line trend; montht = number of months from start of ob-
servation; AFPIIt = whether month t is after AFPII; β2 =
level change after the AFPII; β3 = trend change after the
AFPII; SNPt = whether month t is after SNP; β4 = Level
change after the SNP; β5 = trend change after the SNP;
et = residual error.
The baseline segment was fit with an intercept and a vari-
able estimating trend. We estimate each policy effect by a
variable representing the change in level of the outcome im-
mediately after the policy and a second representing the
change in trend of the post-policy segment. Patients would
experience changes in copayment only when they presented
to fill a prescription after the policy change. We thus defined
a post-policy implementation period of 2months for the pro-
gram to take effect; these periods were excluded in the ITS
models so that we could estimate stable post-intervention ef-
fects. Additionally, we performed a sensitivity analysis consid-
ering the possibility of autocorrelation, assessing the
significance of the Durbin-Watson statistic. We found that
all outcomes have some level of autocorrelation, we compare
the use of “prais” alone, “prais, var rhotype (dw)”, and “prais
var, corc” [18]. We made an option to use Cochrane-Orcutt
procedure “prais var., corc” since it presented the better ad-
justment. The sensitivity analysis showed that small autocor-
relation did not impact the direction, significance of the
findings. (Additional file 1).
We retained all parameters in the models regardless of
statistical significance. We highlight the results with p < 0.05.
To create single number summaries of policy effects, we
calculated estimates of the relative changes in outcomes
compared to expected values based on prior trends in April
2010 and February 2012, about 1 year after the two copay-
ment interventions.
Results
A total of 6,059,643 and 14,447,006 patients received medi-
cines for DM or HTN, respectively, from the FP program.
The mean age was 55 years for diabetes and 56 for hyperten-
sion patients, with females comprising about 60% of patients
for both diseases. The southeast region represented the ma-
jority of patients in the program (Table 1) (Additional file 2).
FP coverage
Annual coverage of unique patients varied from 3.2 to
16.7% for DM and 1.6 to 9.7% for HTN, from 2006 to
2008, while average monthly coverage varied from 0.9 to
3.7% for DM and 0.5 to 2.4% for HTN, respectively. In
2009 and 2010, just after the AFP-II, coverage of unique
patients decreased from 17.4 to 12.9% for DM and 9.8 to
7.1% for HTN, while average monthly coverage de-
creased from 3.9 to 3.2% for DM and 2.4 to 1.9% for
HTN, respectively. After SNP, there was an impressive
increase in coverage of unique patients that reached
40.6% for DM and 32.6% for HTN by the end of follow-
up, while average monthly coverage reached 13.0 and
11.5%, respectively (Table 1).
Number of individuals in FP
During the baseline period prior to the cost sharing
changes, the numbers of individuals covered by the FP
program were about 60 and 73 thousand for DM and
HTN, respectively, with increasing trends of 12 and 31
thousand additional individuals per month. The AFP-II
policy changes were associated with a significant de-
crease in level and trend, resulting in a relative decrease
of over 70% for DM and 85% for HTN diseases by April
2010 (Table 2 and Fig. 1). The free medicines policy
under SNP was associated with a large expansion in FP
participation. The relative increases by February 2012
were 615 and 1507% for DM and HTN, respectively
(Table 2 and Fig. 1).
Total expenditure for DM and HTN
Total expenditures in the program tracked the changes
observed in the number of individuals participating for
both DM and HTN, with expenditures increasing steadily
prior to April 2009, then experiencing relative declines of
69.9 and 93.3% by April 2010, 1 year after AFP-II imple-
mentation, for DM and HTN, respectively (Table 2 and
Fig. 1). The free medicines SNP policy was associated with
relative increases in total FP expenditure of 260 and
1812% for DM and HTN, respectively (Table 2 and
Fig. 1).
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Percentage of expenditures by the Ministry of Health
Prior to 2009, the MoH was responsible for 81.3 and
83.4% of the total expenditures for DM and HTN
medications in the program, with a slightly decreasing
trend. The cost sharing changes introduced by the
AFP-II policy reduced the MoH share of expenditures
at 1 year after the policy change by 14.3 and 16.2%
for DM and HTN, respectively (Table 2 and Fig. 1).
Following the SNP free medicines policy, the MoH
started to cover 100% of medicines expenditures,
representing an increase of 69% for DM and 36% for
HTN by February 2012 (Table 2 and Fig. 1).
Per capita expenditure for DM and HTN treatment
The cost per treatment per person prior to 2009 varied
from R$33.1 to R$31.4 to and R$36.4 to 36.6 for DM
and HTN, respectively, with no significant change fol-
lowing the AFP-II policy change. The free medicines
SNP policy was associated with a decrease of around
R$15 per treatment, representing a reduction over 37%
by February 2012 for both diseases (Table 2 and Fig. 2).
Out of pocket payment
In 2006, patients paid an average of R$6.3 for their
monthly DM and HTN treatment, respectively. The
Table 1 Participants in “Farmácia Popular is Available Here” program by gender, age, region, and specific coverage. Brazil, 2006 to
2012
Variables Diabetes Hypertension
Age (n; mean (SD))
Total 6,059,643 55 (15) 14,447,006 56 (15)
Gender (n, %)a
Female 3,618,239 59.7% 8,666,405 60.0%
Male 2,425,635 40.0% 5,738,940 39.7%
Region (n, %)
North 169,525 2.8% 470,286 3.3%
Northeast 852,271 14.1% 2,127,680 14.7%
Southeast 3,790,268 62.5% 8,333,436 57.7%
South 887,754 14.7% 2,566,954 17.8%
West-Center 359,825 5.9% 948,650 6.6%
Coverage1 Number of individuals in the FP Annual coverage Number of individuals in the FP Annual coverage
2006 186,286 3.2% 348,903 1.6%
2007 746,279 11.2% 1,554,871 6.1%
2008 1,251,049 16.7% 2,711,688 9.7%
2009 1,300,919 17.4% 2,765,155 9.8%
2010 1,041,056 12.9% 2,039,368 7.1%
2011 2,682,000 33.2% 7,008,960 24.3%
2012 3,755,010 40.6% 9,487,841 32.6%
Coverage2 Average individuals per year Average Monthly coverage Average individuals per year Average Monthly coverage
2006 52,004 0.9% 101,945 0.5%
2007 150,409 2.3% 320,338 1.2%
2008 280,316 3.7% 670,006 2.4%
2009 290,382 3.9% 667,345 2.4%
2010 254,860 3.2% 538,718 1.9%
2011 715,403 8.9% 1,722,162 6.0%
2012 1,200,509 13.0% 3,330,403 11.5%
Coverage 1. Numerator is the number of individuals with at least one dispensing within the year (individuals do not repeat)
Coverage 2. Numerator is the average monthly individuals in each year (sum of individuals in each month within 1 year divided by 12 months) (the same
individual can be count in different months in the same year)
For both coverage indicators the denominator is the estimate prevalence for each disease, which means the number of individuals that should be under
treatment. (Brazilian Basic Indicators - http://tabnet.datasus.gov.br/cgi/idb2012/matriz.htm)
aGender missing Diabetes 0.26% Hypertension 0.29%
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AFP-II policy change was associated with an increase in
out of pocket payment of R$6.6 for DM and R$7.6 for
HTN at the time of the intervention, with a relative in-
crease after 1 year of 52.4 and 80% for DM and HTN, re-
spectively (Table 2 and Fig. 2). The full subsidy
introduced by SNP made medicines available free of
charge to patients after 2011.
Estimate of Farmácia Popular program sustainability
Based on the varying prevalence estimates in national
surveys, the percentage of total MoH expenditures on
medicines that would be required to treat all patients
under the free medicines policy would vary from 4.9 to
18.7% for DM, and from 23.1 to 72.1% for HTN patients,
respectively (Table 3).
Discussion
In this paper, we used secondary data from the FP pro-
gram and data from several national surveys to estimate
utilization, government expenditures, and patient out of
pocket payments, for DM and HTN treatment and then
consider these results in the context of FP sustainability.
This unique combination of information is not common
in low- and middle-income countries.
The FP program co-exists with the free-of-charge
medicines supply system in public health facilities, both
of which are governmental mechanisms to provide med-
icines to patients with chronic illness. We studied anti-
hypertension and hypoglycemic treatment, available
free-of-charge in both programs, in order to understand
FP program costs and sustainability.
For both diseases, the interventions were associated
with similar patterns of change for the outcomes ana-
lyzed. The reduction in reference prices in 2009, to-
gether with administrative changes (AFP-II), resulted in
an increase in patient cost sharing and associated drop
out of users. The SNP, on the other hand, resulted in
the opposite effects on these measures.
Affordability, as measured by level of patient out-of-
pocket payment, decreased after AFP-II but improved
substantially when medicines were dispensed for free fol-
lowing the SNP policy. Considering that, prior to the FP
program, patients paid the full price of medicines out-
of-pocket at retail pharmacies, the simple existence of a
government subsidy mechanism increased overall
Fig. 1 Number of individuals and total expenditures in FP and percentage paid by the MoH, and predicted values from segmented regression
models for diabetes and hypertension, by stage of the Farmácia Popular program, Brazil, 2006 to 2012
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affordability over time. This is important since it has
been shown that there is a high burden of medicines ex-
penditures at household level in Brazil [10], despite free-
of-charge medicines dispensing in SUS. Since private
pharmacies are much more widespread than government
health facilities and open for longer hours, this repre-
sented an improvement for patients in both affordability
and convenience.
The effects of the reduction of reference prices follow-
ing the AFP-II policy change have already been dis-
cussed in other publications [23, 24]. More restrictive
enforcement measures were implemented, aimed at re-
ducing corruption [25] and improving control and audit
mechanisms [23], but this may have impaired program
use by patients, judging by reductions in the number of
individuals using the program. Not surprisingly, the SNP
free medicines policy had the opposite effect, increas-
ingly attracting users to FP.
Overall, the policy changes under AFP-II showed dele-
terious effects from both the government and patient
perspectives. Despite reducing MoH overall expenditures
by reducing their level of cost sharing, the savings were
proportional to the number of individuals still using the
program. There were no changes in efficiency, since
there were no significant reductions in expenditure per
treatment. After implementation of the free medicines
SNP policy, overall MoH expenditures increased signifi-
cantly because of increased coverage. However, the cost
per treatment was about 40% more efficient, so the rela-
tive change in expenditures after 1 year of SNP was
700%, despite a 1600% increase in the number of indi-
viduals treated. This improvement in efficiency may be
related to gains from economies of scale in drug pur-
chasing and substitution of generic drugs [26]. We previ-
ously found a growth of 20% in generic antihypertensive
medicines use after SNP [27] as well as evidence of a
75% growth in sales volume for DM and HTN medicines
covered in FP 2011 and 2012 [6].
We found large discrepancies in estimates of the size
of the DM and HTN populations and FP coverage in the
literature [14, 15, 28–30], so we estimated coverage
using two different methods. Our estimates for coverage
of number of unique patients align with PMAQ,
PNAUM, VIGITEL, while PNS is similar to our
Fig. 2 Number of individuals and treatment cost per capita and out of pocket payment, and predicted values from segmented regression models for
diabetes and hypertension, by stage of the Farmácia Popular program, Brazil, 2006 to 2012
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estimates of average number of monthly patients cov-
ered. If we assume that all DM and HTN patients would
choose to obtain their medicines through FP private
pharmacies, the program would consume in 2013 from
30.6 to 79% of the total MoH medicines budget for
treating those two diseases alone. In the same year, the
total estimated spending for primary health care medi-
cines provided free-of-charge in public health facilities
was R$2.26 billion [31]. As argued previously [6], since
private pharmacies are reimbursed according to pre-
scriptions filled and either public or private sector pre-
scriptions are accepted, this poses important concerns
regarding FP sustainability.
Considering the estimated financial outlay that
would be required for MoH to cover all HTN and
DM patients in the country through FP, it is likely
that the program is sustainable only as a complemen-
tary policy and not as a substitute to distribution of
medicines by the SUS. This is in accordance with the
program’s original purpose, which was to cover those
low-income individuals with key chronic illnesses who
used private health care services but could not afford
medicines. However, due largely to deficiencies in the
SUS, the FP came to be used as a substitute channel
for provision of medicines [6]. Despite its positive
impact on access, utilization, and affordability, it is
important to consider financial sustainability when
assessing the value of different medicines provision
mechanisms in the country.
The study limitations include having no data on medi-
cines that are not part of the FP, making it impossible to
evaluate the impact of FP policies on the utilization of
other medicines used to treat diabetes and hypertension.
Furthermore, since we use data from surveys to estimate
program coverage, we need to also consider the limita-
tions of these sources of secondary data.
Table 3 Annual coverage and sustainability estimated for Farmácia Popular Program, (FP, PMAQ, PNAUM,VIGITEL,PNS), Brazil 2007 to
2015
Year Prevalencea Coverage (%) Total MoH
expenditures
on medicines
(in Millions of
reais)h
Estimated Expenditure to cover all people by Farmácia
Popular (as a percentage of total MoH expenditures on
medicines)
FP_
Cov_1b
FP_
Cov_2c
PMAQd PNAUMe VIGITELf PNSg FP_
Cov_1
FP_
Cov_2
PMAQ PNAUM VIGITEL PNS
Diabetes
2007 9.3 11.2 2.3 – – – – 5176.04 9.3 46.1 – – – –
2008 10.3 16.7 3.7 – – – – 5866.20 8.5 37.8 – – – –
2009 10.0 17.4 3.9 – – – – 6765.46 8.5 38.0 – – – –
2010 10.4 12.9 3.2 – – – – 6988.75 10.3 42.0 – – – –
2011 10.3 33.2 8.9 – – 16.7 – 8348.67 4.9 18.5 – – 9.8 –
2012 11.7 40.6 13.0 16.2 – 23.1 – 9656.00 6.0 18.7 15.0 – 10.5 –
2013i 10.9 52.9 21.2 – 18.3 24.8 57.4 11,467.11 5.5 13.7 – 15.8 11.7 5.1
Hypertension
2007 35.8 6.1 1.2 – – – – 5176.04 42.2 205.0 – – – –
2008 38.4 9.7 2.4 – – – – 5866.20 39.2 158.7 – – – –
2009 37.7 9.8 2.4 – – – – 6765.46 40.7 168.8 – – – –
2010 36.8 7.1 1.9 – – – – 6988.75 43.9 166.2 – – – –
2011 36.8 24.3 6.0 – – 16.1 – 8348.67 23.1 94.0 – – 37.9 –
2012 36.8 32.6 11.5 15.3 – 22.8 – 9656.00 25.3 72.1 54.2 – 36.2 –
2013i 36.5 39.2 15.1 – 16.0 20.9 35.9 11,467.11 25.1 65.2 – 61.5 47.0 27.4
a. prevalence in the population 35 years old and older. VIGITEL (Brazilian Basic Indicators - http://tabnet.datasus.gov.br/cgi/idb2012/matriz.htm)
bCoverage 1. Estimated coverage in FP - Numerator is the number of individuals with at least one dispensing within the year (individuals do not repeat)
cCoverage 2. Estimated coverage in FP Numerator is the average monthly individuals in each year (sum of individuals in each month within 1 year divided by 12
months) (the same individual can be count in different months in the same year)
dPMAQ = National Program for Improving Access and Quality of Primary Health Care (PMAQ); source: http://dab.saude.gov.br/portaldab/ape_pmaq.php
ePNAUM= Brazilian Survey on Medicine Access, Utilization and Rational Use of Medicines. Source: (Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e
Insumos Estratégicos em Saúde. Departamento de Assistência Farmacêutica e Insumos Estratégicos et al., In press)
fVIGITEL = Surveillance of risk-factor for chronic diseases through telephone interviews; Source (Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde.
Secretaria de Ciência, Tecnologia e Insumos Estratégicos, 2015)
gPNS = National Health Survey; Source: (Sarmento Costa et al., 2016)
hMinistry of Health – national accounts (Rondineli et al., 2016)
i2013 AFP coverage is estimated based on coverage linear regression after February 2011
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Individuals are allowed to be in multiple treatments.
Per-capita cost was considered the total cost of all medi-
cines covered in the month divided by the number of in-
dividuals in treatment under FP. As we used data at
individual level, we think this is a reasonable approach,
assuming that the distribution of medicines users would
be similar in SUS and FP.
Despite increased investment over time in SUS strength-
ening, there was not any specific new policy or interven-
tion change that occurred at the same point in time of the
studied interventions [6, 12]. Therefore, since we con-
trolled for pre-existing trend and the small autocorrelation
addressed in the analysis, we can infer that the observed
changes estimated in this paper are related to the inter-
ventions and not to another confounding policy.
Conclusion
The FP greatly increased its coverage during the period ana-
lyzed and substantially improved the affordability of chronic
illness treatment when medicines for diabetes and hyperten-
sion became free-of-charge in 2011. There was also an im-
provement in government expenditure efficiency, since the
treatment cost per capita declined after 2011 due to purchas-
ing leverage. However, overall MoH expenditures in the FP
program increased substantially because of the increased
number of users. FP appears to be sustainable only as a com-
plementary policy, not as replacement for the SUS provision
of medicines at primary healthcare facilities. Considering the
magnitude of the FP program in the Brazilian pharmaceutical
market, future studies should address the optimum treat-
ment cost per capita, especially in the context of the Brazilian
economic and political crises.
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